Country: Israel
Language: English
Source: Ministry of Health
DABIGATRAN ETEXILATE AS MESILATE
BOEHRINGER INGELHEIM ISRAEL LTD.
B01AE07
CAPSULES
DABIGATRAN ETEXILATE AS MESILATE 150 MG
PER OS
Required
BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY
DABIGATRAN ETEXILATE
Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
2015-02-28
Pradaxa 150 mg capsules Updated Patient Information Leaflet Boehringer Ingelheim June 2020 Page 1 of 7 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 The dispensing of this medicine requires a physician’s prescription PRADAXA ® 150 MG CAPSULES ACTIVE INGREDIENT: Each capsule of PRADAXA 150 contains: 150 mg dabigatran etexilate (as mesilate) Inactive ingredients and allergens: see Section 6. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, ask your physician or the pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. Patient information card: This card contains important safety information which you should know prior to beginning treatment with Pradaxa and during the treatment with Pradaxa. The card contains information intended for both the patient and the healthcare staff. It provides guidance for the patients on how to minimize the risk of bleeding resulting from treatment with any anticoagulant agent. In addition, the card contains personal details of the patient and information regarding Pradaxa for the healthcare staff. Present this card to any healthcare professional involved in your treatment. 1. WHAT IS THIS MEDICINE INTENDED FOR? Pradaxa contains the active ingredient dabigatran etexilate which belongs to a group of medicines called anticoagulants. Pradaxa is intended for adults, to: • prevent stroke and systemic embolism in adult patients suffering from irregular heart beat (atrial fibrillation) that is not in addition to a heart valve disease. • treat thrombosis in the leg veins (deep vein thrombosis (DVT)) and in the pulmonary blood vessels (pulmonary embolism (PE)), and prevent recurrent thrombosis in these blood vessels. THERAPEUTIC GROUP: Anticoagulants. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE I Read the complete document
Pradaxa 150 Prescribing Information Boehringer Ingelheim January 2022 Boehringer Ingelheim Israel Page 1 of 38 1 PRADAXA 150 DABIGATRAN ETEXILATE 150 MG HardCapsules PRESCRIBING INFORMATION 1. NAME OF THE MEDICINAL PRODUCT Pradaxa 150 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Each hard capsule contains 150 mg of dabigatran etexilate (as mesilate). For the full list of excipients, see section 6.1. The marketing of Pradaxa is subject to a risk management plan (RMP) including a “Patient safety information card”. The “Patient safety information card”, emphasizes important safety information that the patient should be aware of before and during treatment. Please explain to the patient the need to review the card before starting treatment. _Please provide patient safety information card (patient card) to each patient who is prescribed with _ _Pradaxa. Explain to the patient the implications of anticoagulant treatment including the need for _ _compliance. Please also explain the signs of bleeding and when to seek medical attention. _ _The patient card will inform physicians and dentists about the patient‘s anticoagulation treatment _ _and will contain emergency contact information. The patient should be instructed to carry the _ _patient alert card at all times and present it to every health care provider_. Pradaxa 150 Prescribing Information Boehringer Ingelheim January 2022 Boehringer Ingelheim Israel Page 2 of 38 2 3. PHARMACEUTICAL FORM Hard capsule. Capsules with light blue, opaque cap and white, opaque body of size 0 (approx. 22 x 8 mm) filled with yellowish pellets. The cap is imprinted with the Boehringer Ingelheim company symbol, the body with “R150”. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF ). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _PREVENTION OF ST Read the complete document